This report was first published by Endpoints News. To see the original version, click here
Zealand Pharma is out with the Phase 2 data for an amylin analog that spurred one of the industry’s largest-ever obesity drug deals last year.
The drug, called petrelintide, led to up to 10.7% mean body weight loss at week 42 as compared to 1.7% for placebo in a Phase 2 study dubbed ZUPREME-1, Zealand said Thursday afternoon. The trial included 493 people with obesity or overweight at a mean BMI of 37 kg/m².
您已阅读12%（500字），剩余88%（3790字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。